N-(tert-butyl)-4-iodoaniline | 40686-52-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(tert-butyl)-4-iodoaniline
• 英文别名: p-Iod-N-t-butylanilin；tert-Butyl-(4-iodo-phenyl)-amine；N-tert-butyl-4-iodoaniline
• CAS: 40686-52-0
• 化学式: C₁₀H₁₄IN
• 分子量: 275.132
• InChiKey: ACPMDQXYKONFMW-UHFFFAOYSA-N

物化性质

• 沸点：
  295.2±23.0 °C(Predicted)
• 密度：
  1.524±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-(tert-butyl)-4-iodoaniline 在 copper(l) iodide 、 四(三苯基膦)钯 、 三乙胺 、 二异丙胺 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 15.0h， 生成 4-((10-bromoanthracen-9-yl)ethynyl)-N-(tert-butyl)aniline
  参考文献：
  名称：

  Fluorescent nucleosides with ‘on–off’ switching function, pH-responsive fluorescent uridine derivatives

  摘要：

  We synthesized various pH-responsive fluorescent deoxyuridine derivatives (1a-g). These fluorescent nucleosides exhibited distinctive fluorescence at 470-600 nm in aqueous solvents containing methanol only at acidic to neutral pH values. In particular, 1f exhibited strong fluorescence only at pH range of 3.1-7.2 with a pK(a) of 6.1. Such pH-sensitive fluorescent nucleosides can be used as 'on-off' fluorescence switch for monitoring pH change in biological systems, particularly for cancer cell detection. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.02.092
• 作为产物：
  描述：

  N-(tert-butyl)-O-benzoylhydroxylamine 、 4-碘苯硼酸新戊二醇酯 在 copper(I) trifluoromethanesulfonate benzene 、 cesium fluoride 、 双(二环己基膦基苯基)醚 作用下， 以 四氢呋喃 为溶剂， 反应 3.5h， 以91%的产率得到N-(tert-butyl)-4-iodoaniline
  参考文献：
  名称：

  实用的催化合成位阻苯胺的方法。

  摘要：

  描述了一种合成位阻苯胺的实用催化方法。芳基和杂芳基硼酸酯的胺化反应是使用从... ...原位制备的催化剂完成的。

  DOI：

  10.1039/c5cc03565a

文献信息

• HYDROXYINDOLE CARBOXYLIC ACID BASED INHIBITORS FOR ONCOGENIC SRC HOMOLOGY-2 DOMAIN CONTAINING PROTEIN TYROSINE PHOSPHATASE-2 (SHP2)
  申请人：INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION

  公开号：US20160102054A1

  公开（公告）日：2016-04-14

  Inhibitors of protein tyrosine phosphatases are disclosed. The inhibitors include hydroxyindole carboxylic acids having a linker and an amine scaffold that are potent inhibitors of Src homology 2-domain containing protein tyrosine phosphatase-2.

  本发明公开了蛋白酪氨酸磷酸酶的抑制剂。这些抑制剂包括具有连接基和胺支架的羟基吲哚羧酸，它们是Src同源2-含有蛋白酪氨酸磷酸酶的有效抑制剂。
• SHP2 INHIBITORS AND METHODS OF TREATING AUTOIMMUNE AND/OR GLOMERULONEPHRITIS-ASSOCIATED DISEASES USING SHP2 INHIBITORS
  申请人：INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION

  公开号：US20160374988A1

  公开（公告）日：2016-12-29

  Methods are disclosed herein for administering a oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitor for treating autoimmune and/or glomerulonephritis-associated diseases, and in particular, Systemic Lupus Erythematosus (SLE).
• GLUCAGON ANTAGONISTS
  申请人：Ligand Pharmaceuticals, Inc.

  公开号：US20170216229A1

  公开（公告）日：2017-08-03

  Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof.
• METHODS OF TREATING AUTOIMMUNE AND/OR GLOMERULONEPHRITIS-ASSOCIATED DISEASES USING SHP2 INHIBITORS
  申请人：Indiana University Research and Technology Corporation

  公开号：US20180071252A1

  公开（公告）日：2018-03-15

  Methods are disclosed herein for administering a oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitor for treating autoimmune and/or glomerulonephritis-associated diseases, and in particular, Systemic Lupus Erythematosus (SLE).
• Glucagon Antagonists
  申请人：LIGAND PHARMACEUTICALS,INC.

  公开号：US20190099391A1

  公开（公告）日：2019-04-04

  Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof.